Halozyme Therapeutics | HALO - Despesas Operacionais





Despesas Operacionais Alterar Data
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amarin USD 51.48M 113K 2025-12
Amgen USD 5.9B 773M 2025-12
Baxter International USD 3.19B 554.4M 2025-12
Cara Therapeutics USD 5.94M 983K 2025-09
Cytokinetics USD 196.12M 27.43M 2025-12
DBV Technologies USD 37.05M 4.06M 2025-09
Eli Lilly USD 10.31B 1.09B 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
MannKind USD 119.64M 56.29M 2025-12
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
United Therapeutics USD 804.8M 5.79B 2025-12
Vanda Pharmaceuticals USD 466M 20.33M 2025-09